Granulocyte colony-stimulating factor and its receptor

Production of IL-8, IL-17, IFN-gamma and IP-10 in human astrocytes correlates with alphavirus attenuation

“…Granulocyte colony stimulating factor (G-CSF) was upregulated post exposure to the SIN/ZPC chimera, beginning at approximately 30 h, to as much as 3.9-fold elevation above controls by 48 h. G-CSF is a growth factor with a role in systemic homeostasis by regulating the production of neutrophils from stem cells in the bone marrow (Demetri and Griffin, 1991). More recent studies have shown a neuroprotective effect following treatment with G-CSF in response to various injuries or other stimuli such as ischemia (Gibson et al, 2005;Komine-Kobayashi et al, 2006;Park et al, 2005;Solaroglu et al, 2006b;Schneider et al, 2005;Sheibani et al, 2004).…”

Granulocyte colony‐stimulating factor (G‐CSF) positive effects on muscle fiber degeneration and gait recovery after nerve lesion in MDX mice

“…Therapeutic use of granulocyte colony-stimulating factor (G-CSF) has been reported for some tissues, such as skeletal muscle, spinal cord, and peripheral nerve (Mirski et al 2003;Stratos et al 2007;Pitzer et al 2008;Hara et al 2011;Pollari et al 2011;Simões and Oliveira 2012a,b). G-CSF was initially identified as a hematopoietic cytokine and has been used in both basic research studies and in the clinic for the mobilization of hematopoietic stem cells (Welte et al 1996;Demetri and Griffin 1999;Metcalf 2008). Recent studies have suggested that G-CSF also plays roles in cell differentiation, proliferation, and survival (Avalos 1996;Harada et al 2005;Zaruba et al 2009).…”

“…Recent studies have suggested that G-CSF also plays roles in cell differentiation, proliferation, and survival (Avalos 1996;Harada et al 2005;Zaruba et al 2009). The administration of granulocyte colony-stimulating factor (G-CSF) is known to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood (Demetri and Griffin 1999) and is used to treat neutropenia after cytostatic therapy. G-CSF has a wide variety of actions; it reduces apoptosis, drives neurogenesis and angiogenesis, and attenuates inflammation (Boneberg et al 2000;Saito et al 2002;Shyu et al 2004;Lee et al 2005;Schneider et al 2005;Kawada et al 2006).…”

Renewed Interest in Granulocyte Transfusion Therapy

“…Neutropenia remains the principal factor limiting the use of chemotherapy for the treatment of cancer and a major cause of morbidity following bone marrow transplantation (Pizzo, 1993;Strauss, 1993;. The discovery and clinical development of the colony-stimulating factors, namely granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), have had a major impact to reduce the duration and severity of neutropenia in these circumstances, but the problem of neutropenia has not been solved (Groopman et al, 1989;Weisbart et al, 1989;Demetri & Griffin, 1991;Lieschke & Burgess, 1992;Dale et al, 1995;Gasson, 1991;Crawford et al, 1991;Gisselbrecht et al, 1994;Gabrilove et al, 1988a, b;Maher et al, 1994;Neumanitis et al, 1991;deVries et al, 1991;Gerhartz et al, 1993;Ozer, 1994). G-CSF and GM-CSF are only effective if the patient has a sufficient population of responsive haemopoietic precursor cells.…”

“…G-CSF was first identified as a stimulatory factor present in the serum of animals administered endotoxin (Nicola et al, 1983). It is now recognized as the critical determinant of the blood neutrophil count (Demetri & Griffin, 1991;Lieschke & Burgess, 1992;Hammond et al, 1991;Lieschke et al, 1994). Deficiencies of G-CSF cause neutropenia (Hammond et al, 1991;Lieschke et al, 1994) and increased endogenous levels of G-CSF, which occurs with overproduction of this cytokine by certain tumours, results in neutrophilia (Morstyn et al, 1988;Gabrilove et al, 1988a;Chatta et al, 1994).…”